Advertisement
Canada markets open in 1 hour 32 minutes

  • S&P/TSX

    22,259.47
    +312.06 (+1.42%)
     

  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     

  • DOW

    38,852.27
    +176.59 (+0.46%)
     

  • CAD/USD

    0.7309
    -0.0012 (-0.16%)
     

  • CRUDE OIL

    78.25
    -0.23 (-0.29%)
     

  • Bitcoin CAD

    86,889.64
    -928.19 (-1.06%)
     

  • CMC Crypto 200

    1,322.91
    -42.21 (-3.09%)
     

  • GOLD FUTURES

    2,322.00
    -9.20 (-0.39%)
     

  • RUSSELL 2000

    2,060.67
    +24.95 (+1.23%)
     

  • 10-Yr Bond

    4.4890
    -0.0110 (-0.24%)
     

  • NASDAQ futures

    18,160.25
    -35.25 (-0.19%)
     

  • VOLATILITY

    13.57
    +0.08 (+0.59%)
     

  • FTSE

    8,297.65
    +84.16 (+1.02%)
     

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • CAD/EUR

    0.6786
    -0.0006 (-0.09%)
     

Today's Research Reports on Advanced Proteome Therapeutics, Cronos Group, Medicure and Helix BioPharma

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / October 4, 2017 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Advanced Proteome Therapeutics Corporation
https://rdinvesting.com/news/?ticker=APC.V

Cronos Group Inc.
https://rdinvesting.com/news/?ticker=MJN.V

Medicure Inc.
https://rdinvesting.com/news/?ticker=MPH.V

Helix BioPharma Corp.
https://rdinvesting.com/news/?ticker=HBP.TO

ADVERTISEMENT

Advanced Proteome Therapeutics Corporation's stock had no change Tuesday, to close the day at $0.05. The stock recorded a trading volume of 5,000 shares, which was below its three months average volume of 68,848 shares. In the last year, Advanced Proteome Therapeutics Corporation's shares have traded in a range of 0.04 - 0.10. The share price has gained 42.86% from its 52-week low. The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $0.05 is below its 200-day moving average of $0.06.

Access RDI's Advanced Proteome Therapeutics Corporation Research Report at:
https://rdinvesting.com/news/?ticker=APC.V

On Tuesday, shares in Cronos Group Inc. recorded a trading volume of 263,273 shares, which was above the three months average volume of 172,342 shares. The stock ended the day 2.61% higher at 2.75. The share price has gained 198.91% from its 52-week low with a 52-week trading range of 0.92 - 3.54.The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $2.39 is greater than its 200-day moving average of $2.34. Shares of Cronos Group Inc. are trading at a Price to Earnings ratio of 2,750.00. Shares of Cronos Group have gained approximately 3.77 percent year-to-date.

Access RDI's Cronos Group Inc. Research Report at:
https://rdinvesting.com/news/?ticker=MJN.V

Medicure Inc.'s stock moved 5.17% lower Tuesday, to close the day at $8.25. The stock recorded a trading volume of 76,781 shares, which was above its three months average volume of 6,348 shares. In the last year, Medicure Inc.'s shares have traded in a range of 5.48 - 10.67. The share price has gained 50.55% from its 52 week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $7.90 is below its 200-day moving average of $8.10. Shares of the company are trading at a Price to Earnings ratio of 6.04. Shares of Medicure have fallen approximately 19.9 percent year-to-date.

Access RDI's Medicure Inc. Research Report at:
https://rdinvesting.com/news/?ticker=MPH.V

On Tuesday, shares in Helix BioPharma Corp. recorded a trading volume of 1,000 shares, which was below the three months average volume of 2,057 shares. The stock ended the day 3.33% lower at 0.87. The share price has gained 74.00% from its 52-week low with a 52-week trading range of 0.50 - 1.78.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $0.90 is below its 200-day moving average of $0.96. Shares of Helix BioPharma have fallen approximately 43.51 percent year-to-date.

Access RDI's Helix BioPharma Corp. Research Report at:
https://rdinvesting.com/news/?ticker=HBP.TO

Our Actionable Research on Advanced Proteome Therapeutics Corporation (TSX-V: APC.V), Cronos Group Inc. (TSX-V: MJN.V), Medicure Inc. (TSX-V: MPH.V) and Helix BioPharma Corp. (TSX: HBP.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com